Covid-19

#Covid-19 #Diagnostics #Manufacturing

GADx launches as social enterprise for diagnostics  

Diagnostics company Mologic and its sister company Global Access Diagnostics (GAD) have combined their expertise to form a new business aimed at addressing the gaps in the provision of diagnostics, with a focus on expanding affordable access to quality tests.  Global Access Diagnostics (GADx) is the first… Read More

#News

#Biopharma #Covid-19 #mRNA #Vaccines

mRNA vaccines – how do we keep up with the new kid on the block? 

By Greg Kulnis  - Vice President, Customer Solutions (Infectious Disease) for Nexelis The Covid-19 pandemic has led to unprecedented collaboration and acceleration in vaccine development. In the past two years, many leading pharmaceutical and biotech companies have shifted their research and development (R&D) focus to tackle the threat of SARS-CoV-2. Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Covid-19 #Machine learning #SLAS Europe

A different future is possible with the right data

Listen to this article on the DDW Podcast: Philip Gribbon is Head of Discovery Research at the Fraunhofer Institute for Translational Medicine and Pharmacology in Hamburg, Germany. Ahead of his participation in a Data Sharing panel at SLAS Europe 2022, Gribbon tells Megan Thomas about the importance and lasting impact of… Read More

#Exclusive Content #Opinion #Trends & Analysis

#Biopharma #Covid-19 #Pandemic

NIAID to establish research centres to combat future pandemics  

The National Institute of Allergy and Infectious Diseases (NIAID) is investing $577 million to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern, the organisation has announced.   The AViDD centers will conduct multidisciplinary research to develop candidate Covid-19 antivirals and others targeting specific viral… Read More

#Covid-19 #News

#Covid-19 #Drug discovery #Genetics

Biotechs partner to understand genetics of long Covid   

A partnership between life sciences companies PrecisionLife and Sano Genetics aims to drive insights into the genetics of long Covid and potentially identify new treatments.    The companies will analyse Sano Genetics’ data of 3,000 adults suffering from long Covid symptoms using PrecisionLife’s combinatorial analytics platform… Read More

#Covid-19 #News

#Business #Covid-19 #GSK

What’s behind GSK’s strong Q1 earnings?  

DDW Deputy Editor Reece Armstrong looks at the key points of GSK’s first quarter earnings.   UK pharmaceutical company GSK has reported strong financial earnings for the first quarter of 2022.  The pharma giant reported total sales in Q1 of £9.8 billion, crediting much of that to the company’s biopharma offerings. … Read More

#Business & Investment #News

#Antivirals #Covid-19 #WHO

WHO recommends Pfzier’s antiviral combo for Covid-19 patients  

The World Health Organisation (WHO) has strongly recommended a combination of antiviral drugs for patients at a high risk of hospital admission due to Covid-19.   The WHO is recommending Pfizer’s oral antiviral drug (a combination of nirmatrelvir and ritonavir tablets) for patients with non-severe covid-19 who are… Read More

#News

#Biopharma #Clinical trial #Covid-19 #Genetics #Vaccines

This week in drug discovery (18-22 April)  

News round-up by DDW’s Reece Armstrong for 18-22 April    Covid-19, the link between ageing and genetic mutations, alongside funding opportunities for drug developers are some of the themes of this week’s news round-up.   1: Researchers shed light on ageing in new… Read More

#News

#Covid-19 #GlobalData #Manufacturing

Opportunities linked to increase in FDA approvals of Covid-19 products  

An increasing number of approvals and Emergency Use Authorisations (EUAs) by the Food and Drug Administration (FDA) for Covid-19 vaccines and drugs, as well as cell and gene therapies, is helping provide manufacturing opportunities for contract manufacturing organisations (CMOs).  This is according to GlobalData’s latest report –… Read More

#News

#Covid-19 #HIV #Immunology / Virology & Vaccines

ReiThera and Exothera collaborate to develop vaccines for Africa

Biotech company ReiThera is collaborating with contract development and manufacturing organisation (CDMO) Exothera on a project to develop Covid-19 and HIV vaccines for low-and middle-income countries (LMIC). The collaboration will see the companies develop and deliver new low-cost vaccines based on ReiThera’s GRAd technology platform for LMICs in Africa. Exothera… Read More

#News

#Clinical trials #Covid-19 #Healthcare #HIV #Malaria #Public health

World Health Day: We celebrate global drug discovery

As we celebrate World Health Day, Lu Rahman looks at some of the key drug discovery and development successes over the last year that have significantly helped improved the health and wellbeing of the global population.   Malaria breakthroughs  According to The World Health Organization (WHO) more than a million people in Africa… Read More

#Editor's Choice #Exclusive Content #News

#Arthritis #Clinical trials #Covid-19 #Drug therapy

Covid-19 study boosts Swedish rheumatoid arthritis programme 

Cyxone, a Swedish clinical stage biotech company developing disease modifying therapies for diseases such as rheumatoid arthritis (RA), confirms the previously demonstrated favourable safety and tolerability profile for its drug candidate Rabeximod, in the Clinical Study Report from its exploratory Phase II study in Covid-19 patients.   Other… Read More

#News

#Covid-19 #Funding

This week in drug discovery (28 March – 1 April) 

News round-up by DDW’s Megan Thomas for 28 March – 1 April, 2022  From Covid updates to life-saving investments, this week’s news shows how valuable the drug discovery industry is and the impact it makes.  1. Covid-19 approval milestone for those who can’t be… Read More

#News

#Covid-19 #Drug discovery #Research

Experts evaluate the effects of ACE2-mediated Covid-19 infection 

Bachem, a Swiss technology company active in the fields of chemistry, biochemistry and pharmaceuticals, as well as the development and production of peptides and oligonucleotides, analyses the findings from scientific research about the relationship between ACE2 and SARS-CoV-2.   Covid-19 has impacted almost everyone’s lives, whether through personal experience of infection… Read More

#Covid-19 #Exclusive Content #News

#AstraZeneca #Covid-19 #Marketing approval authorisation #MHRA

Covid-19 approval milestone for those who can’t be vaccinated 

AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab) has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) and is the first antibody combination for pre-exposure prophylaxis (PrEP) against Covid-19 licensed in Great Britain.   The use of this medicine is for adults who are not currently… Read More

#News #Trending News